Download PDF
Evid Based Spine Care J 2012; 03(02): 035-041
DOI: 10.1055/s-0031-1298616
Systematic review
© AOSpine International Stettbachstrasse 6 8600 Dübendorf, Switzerland

The use of rhBMP in spine surgery: is there a cancer risk?

John G. DeVine
1   Eisenhower Army Medical Center, Ft Gordon, GA, USA
,
Joseph R. Dettori
2   Spectrum Research Inc, Tacoma, WA, USA
,
John C. France
3   Department of Orthopaedics, West Virginia University, Morgantown, WV, USA
,
Erika Brodt
2   Spectrum Research Inc, Tacoma, WA, USA
,
Robert A. McGuire
4   Department of Orthopaedic Surgery and Rehabilitation, University of Mississippi Medical Center, Jackson, MS, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2012 (online)

   Permissions and Reprints

Abstract

Study design: Systematic review.

Study rationale: Some have noted several safety issues associated with the use of bone morphogenetic proteins (BMPs), including cancer risk, stating both BMP and their receptors had been isolated from human tumors. In addition, data presented to the US Food and Drug Administration (FDA) on the product AMPLIFY™ (rhBMP-2, 40 mg) revealed a higher number of cancers in the investigational group compared with the control.

Objective: To independently review the cancer risk of rhBMP-2 use in spine fusion as published in the peer-reviewed literature and in the publicly available FDA data summaries.

Methods: A systematic review of the literature was undertaken for articles published through January 2012. Pubmed, Cochrane, National Guideline Clearinghouse Databases as well as bibliographies of key articles were searched. Two independent reviewers revised articles. Inclusion and exclusion criteria were set and each article was subjected to a predefined quality-rating scheme.

Results: Five published peer-reviewed studies and two FDA safety summaries reported the occurrence of cancer in patients treated with spinal fusion using rhBMP-2 or rhBMP-7. Cancer data for on-label use of rhBMP-2 (InFUSE™) were reported in the FDA data summary but not in one published pivotal study. The risk of cancer was same in both the rhBMP-2 and control groups, 0.7% after 24 months. Off-label use of rhBMP for posterolateral fusion (PLF) was associated with a slightly higher risk of cancer compared with controls in three randomized controlled trials and one poorly conducted retrospective cohort study at various follow-ups. In PLF the risk of cancer was 3.8% using 40 mg of BMP-2 compared with 0.9% in the control group. Two RCTs evaluating rhBMP-7 reported a cancer risk of 12.5% and 5.6% in the rhBMP-7 group compared with 8.3% and 0% in the control groups, respectively. The differences in these studies were not statistically significant; however, the sample sizes for these studies were small.

Conclusions: Cancer risk with BMP-2 may be dose dependent, illustrating the need to continue to study this technology and obtain longer follow-up on patients currently enrolled in the FDA trials. Additionally, refined guidelines regarding the routine use of BMPs should be developed, taking into account the FDA summary data that is not routinely scrutinized by the practicing surgeon.

This systematic review was funded by AOSpine.


 

  • References

  • 1 Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976) 2002; 27 (Suppl. 16) S40-48
    CrossrefPubMedGoogle Scholar
  • 2 Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11 (6) 471-491
    CrossrefPubMedGoogle Scholar
  • 3 Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED) for P050036 Medtronic’s AMPLIFY™ rhBMP-2 Matrix. Orthopaedic and Rehabilitation Devices Advisory Panel. Available at: http://www.fda.gov/​downloads/​advisorycommittees/​committeesmeetingmaterials/​medicaldevices/​medicaldevicesadvisorycommittee/​orthopaedicandrehabilitationdevicespanel/​ucm220079.pdf
    PubMedGoogle Scholar
  • 4 Delawi D, Dhert WJ, Rillardon L , et al. 2010; A prospective, randomized, controlled, multicenter study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety and feasibility. Spine (Phila Pa 1976) 2010; 35 (12) 1185-1191
    CrossrefPubMedGoogle Scholar
  • 5 Vaccaro AR, Anderson DG, Patel T , et al. Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976) 2005; 30 (24) 2709-2716
    CrossrefPubMedGoogle Scholar
  • 6 Vaccaro AR, Patel T, Fischgrund J , et al. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976) 2004; 29 (17) 1885-1892
    CrossrefPubMedGoogle Scholar
  • 7 Vaccaro AR, Whang PG, Patel T , et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2008; 8 (3) 457-465
    CrossrefPubMedGoogle Scholar
  • 8 Dimar 2nd JR, Glassman SD, Burkus JK , et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009; 91 (16) 1377-1386
    CrossrefPubMedGoogle Scholar
  • 9 Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED) for P000058 Medtronic’s InFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device. Orthopaedic and Rehabilitation Devices Advisory Panel. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf/P000058b.pdf
    PubMedGoogle Scholar
  • 10 Latzman JM, Kong L, Liu C , et al. 2010; Administration of human recombinant bone morphogenetic protein-2 for spine fusion may be associated with transient postoperative renal insufficiency. Spine (Phila Pa 1976) 2002; 35 (7) E231-237
    PubMedGoogle Scholar
  • 11 Mines D, Gu Y, Kou TD , et al. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2011; 20 (2) 111-118
    CrossrefPubMedGoogle Scholar
  • 12 Burkus JK, Gornet MF, Dickman CA , et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002; 15 (5) 337-349
    CrossrefPubMedGoogle Scholar
  • 13 Baron JA, Weiderpass E. An introduction to epidemiological research with medical databases. Ann Epidemiol 2000; 10 (4) 200-204
    CrossrefPubMedGoogle Scholar
  • 14 Lange LL, Jacox A. Using large data bases in nursing and health policy research. J Prof Nurs 1993; 9 (4) 204-211
    CrossrefPubMedGoogle Scholar
  • 15 Cowper DC, Hynes DM, Kubal JD , et al. Using administrative databases for outcomes research: select examples from VA Health Services Research and Development. J Med Syst 1999; 23 (3) 249-259
    CrossrefPubMedGoogle Scholar
  • 16 Connell FA, Diehr P, Hart LG. The use of large data bases in health care studies. Annu Rev Public Health 1987; 8: 51-74
    CrossrefPubMedGoogle Scholar
  • 17 Flood AB. Peaks and pits of using large data bases to measure quality of care. Int J Technol Assess Health Care 1990; 6 (2) 253-262
    CrossrefPubMedGoogle Scholar
  • 18 Thawani JP, Wang AC, Than KD , et al. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010; 66 (2) 233-246 , discussion 246
    CrossrefPubMedGoogle Scholar
  • 19 Cahill KS, Chi JH, Day A , et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009; 302 (1) 58-66
    CrossrefPubMedGoogle Scholar

    • Reference Editorial Perspective

    • 1 Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11 (6) 471-491
      CrossrefPubMedGoogle Scholar